AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,685 | -80.1% | 6,183 | -68.2% | 0.00% | -100.0% |
| Q2 2023 | $319,976 | -69.1% | 19,416 | -82.8% | 0.00% | -75.0% |
| Q1 2023 | $1,034,778 | +441.7% | 112,967 | +323.5% | 0.00% | – |
| Q4 2022 | $191,007 | -55.2% | 26,677 | -57.3% | 0.00% | – |
| Q1 2022 | $426,000 | -21.8% | 62,423 | -7.4% | 0.00% | – |
| Q4 2021 | $545,000 | -16.9% | 67,447 | +0.8% | 0.00% | -100.0% |
| Q3 2021 | $656,000 | +365.2% | 66,888 | +216.8% | 0.00% | – |
| Q4 2020 | $141,000 | -39.7% | 21,113 | -54.5% | 0.00% | -100.0% |
| Q3 2020 | $234,000 | +1200.0% | 46,443 | +635.9% | 0.00% | – |
| Q2 2019 | $18,000 | +800.0% | 6,311 | +282.7% | 0.00% | – |
| Q1 2019 | $2,000 | -92.6% | 1,649 | -84.1% | 0.00% | – |
| Q4 2018 | $27,000 | -75.9% | 10,349 | -59.4% | 0.00% | -100.0% |
| Q3 2018 | $112,000 | -8.9% | 25,482 | +27.1% | 0.00% | 0.0% |
| Q2 2018 | $123,000 | -48.3% | 20,049 | -38.7% | 0.00% | -50.0% |
| Q1 2018 | $238,000 | +235.2% | 32,715 | +280.0% | 0.00% | – |
| Q4 2017 | $71,000 | – | 8,609 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |